Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Octreotide implant versus Sandostatin LAR in acromegaly
2008-003327-23Phase 3Completed
- Sponsor
- Endo International plc
- Start
- Jul 2008
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, open-label trial of octreotide in acromegaly (2 arms), sponsored by Endo International plc. Primary endpoints: Average growth hormone concentration over 24 weeks, Average insulin-like growth factor 1 concentration over 24 weeks and 1 more. Started Jul 2008; status: completed.
02
Drugs
octreotide
03
Conditions
acromegaly
Beyond the preview
Go deeper on 2008-003327-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-003327-23.